Articles

  • May 31, 2024 | comdirect.de | Krzysztof Narkiewicz

    ^Allschwil, Switzerland - May 31, 2024Idorsia Ltd (SIX: IDIA) today announced that data from the Phase 3 study ofaprocitentan, Idorsia's endothelin receptor antagonist, will be presented byProf. Krzysztof Narkiewicz, MD, PhD, at the European Society of Hypertension's33(r)(d) European Meeting of Hypertension and Cardiovascular Protection, takingplace in Berlin, Germany, May 31 - June 3, 2024.

Contact details

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →